The latest price target for Oncternal Therapeutics (NASDAQ:ONCT) was reported by Northland Capital Markets on September 12, 2024. The analyst firm set a price target for $2.00 expecting ONCT to rise to within 12 months (a possible 20.12% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Oncternal Therapeutics (NASDAQ:ONCT) was provided by Northland Capital Markets, and Oncternal Therapeutics downgraded their market perform rating.

The last upgrade for Oncternal Therapeutics Inc happened on December 4, 2023 when Brookline Capital raised their price target to $2. Brookline Capital previously had a hold for Oncternal Therapeutics Inc.

The last downgrade for Oncternal Therapeutics Inc happened on September 12, 2024 when Northland Capital Markets changed their price target from N/A to $2 for Oncternal Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncternal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncternal Therapeutics was filed on September 12, 2024 so you should expect the next rating to be made available sometime around September 12, 2025.

While ratings are subjective and will change, the latest Oncternal Therapeutics (ONCT) rating was a downgraded with a price target of $0.00 to $2.00. The current price Oncternal Therapeutics (ONCT) is trading at is $1.67, which is within the analyst’s predicted range.